Abstract
To study the relationship between clinical pathologic characteristics, treatment modalities and prognostic factors in HER-2 (Human Epidermal growth factor Receptor-2) overexpressed breast carcinoma. Major clinico-pathological factors including therapeutic modalities and survival status of 371 breast cancer patients with HER2 over-expression, teated at Yantai Yuhuangding Hospital from March of 2002 to December of 2010 were retrospectively studied, with special attention focused on survival-related factors. The median age of the total 371 patients in this study was 48 years at time of diagnosis, among which, the leading pathological type was infiltrating ductal carcinoma (92.5%); 62.8% presented with a primary tomor larger than 2 cm in diameter at diagnosis, 51.0% had axillary lymph node (ALN) metastases; ER (Estrogen receptor) /PR (Progesterone receptor) double negative occured in 52.8% of cases, and PCNA (proliferation cell nuclear antigen) (+ + +) was found in 55.1%. HER-2 overexpressed patients were usually in advanced stage when the diagnosis was made (72.8% at stages IIA~IIIC). The prognosis and survival were assessed in 259 patients with complete follow-up data. 5-year DFS (disease-free survival) and OS (overall survival) rate was 68.0% and 78.0% respectively. Univariate analysis revealed that age, tumor size, ALN metastases, LVSI (lymph-vascular space involvement), PCNA status, hormonal therapy, chemotherapy cycles, and HER-2 overexpression, correlated closely with the prognosis. ALN metastases, LVSI, PCNA status and chemotherapy cycles were independent predictors of survival. HER-2 overexpressed breast cancer has special clinical and pathological characteristics, with advanced clinical stages and high rate of ER/PR double negative. Lymph node metastases, LVSI, PCNA and chemotherapy cycles are independent predictors of prognosis.
Highlights
IntroductionBreast cancer is one of the most common malignant tumors in women
Materials and MethodsBreast cancer is one of the most common malignant tumors in women
The results revealed that age, tumor size, lymph 2 cm; axillary lymph node (ALN) metastases; LVSI; Proliferating cell nuclear antigen (PCNA) (+++); hormonal node metastases, LVSI, hormonal therapy, chemo cycles therapy, P value were all
Summary
Breast cancer is one of the most common malignant tumors in women. Breast cancer has increased greatly in incidence and is the leading malignant disease in a few areas such as Shanghai in China (Tang, 2000). HER-2 overexpression occurs in approximately 2030% breast cancer patients. Such overexpression points to a particular type of malignant tumor with special clinical and histological characteristics. The clinical pathological characteristics of 317 breast cancer patients with HER-2 overexpression treated at our hospital were studied. Of these patients, 259 had complete follow-up data and formed the patient group for studies to elucidate survival-related factors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.